| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer (NCT04119830) | Roswell Park Cancer Institute | 2022-02-01 |
| A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer (NCT05130060) | Mayo Clinic | 2022-01-10 |
| CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen (NCT05312398) | University of Campania Luigi Vanvitelli | 2021-07-15 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (NCT04511039) | Roswell Park Cancer Institute | 2021-06-08 |
| Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (NCT04729322) | M.D. Anderson Cancer Center | 2021-02-22 |
| Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer (NCT05869097) | Hunan Cancer Hospital | 2020-11-01 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer (NCT04044430) | University of California, San Francisco | 2020-08-31 |
| Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. (NCT04483219) | China Medical University, China | 2020-07-24 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839) | City of Hope Medical Center | 2020-05-27 |
| Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer (NCT04117945) | Academic and Community Cancer Research United | 2020-03-03 |
| Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC (NCT06031376) | Hunan Cancer Hospital | 2019-07-01 |
| Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer (NCT05942768) | Hunan Cancer Hospital | 2019-07-01 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (NCT03610490) | M.D. Anderson Cancer Center | 2018-10-16 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (NCT02997228) | National Cancer Institute (NCI) | 2018-01-19 |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (NCT03087071) | M.D. Anderson Cancer Center | 2017-12-29 |
| Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (NCT03043313) | Seagen Inc. | 2017-06-23 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949) | M.D. Anderson Cancer Center | 2016-05-11 |
| Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (NCT02599324) | Pharmacyclics LLC. | 2015-12-01 |
| Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy (NCT06083974) | Assiut University | 2015-01-01 |
| Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma (NCT01639131) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-09-10 |
| Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) (NCT01900717) | Centre Hospitalier Universitaire Dijon | 2011-07-01 |